XTNT Stock Analysis: Buy, Sell, or Hold?
XTNT - Xtant Medical Holdings, Inc.
$0.32
-0.01 (-2.52%)
▼
5d:
+6.52%
30d:
-24.44%
90d:
-30.89%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When XTNT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: XTNT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: XTNT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: XTNT is currently trading at $0.32, which is considered oversold relative to its 30-day fair value range of $0.37 to $0.46. From a valuation perspective, the stock is trading at a discount (Forward PE: -8.3) compared to its historical average (65.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XTNT is in a strong downtrend. Immediate support is located at $0.27, while resistance sits at $0.45.
Market Sentiment: XTNT scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.05 (+215.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XTNT is in a strong downtrend. Immediate support is located at $0.27, while resistance sits at $0.45.
Market Sentiment: XTNT scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.05 (+215.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.37 -
$0.46
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 215.0% below Wall St target ($1.05)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.37 -
$0.46
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.27
Resistance Level
$0.45
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.33
Wall Street Target
$1.05
(+215.0%)
Revenue Growth (YoY)
-35.0%
Profit Margin
-10.2%
PE vs Historical
-8.3 vs 65.2
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XTNT showing a specific setup today?
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$108 | 39 SELL |
